Preeclampsia is a leading cause of maternal and fetal/neonatal mortality and morbidity
worldwide. The early identification of patients with an increased risk for preeclampsia is …

Worldwide the prevalence of preeclampsia (PE) ranges from 3 to 8% of pregnancies. 8.5
million cases are reported yearly, but this is probably an underestimate due to the lack of …

Objective: Preeclampsia (PE) has been classified into early-and late-onset disease. These
two phenotypic variants of PE have been proposed to have a different pathophysiology …

Objective. Changes in the maternal plasma concentrations of angiogenic (placental growth
factor (PlGF) and vascular endothelial growth factor (VEGF)) and anti-angiogenic factors …

Background Early assessment before the establishment of placental dysfunction has the
potential to improve treatment and prognosis for clinical practice. The objective of the study …

Abstract Preeclampsia (PE) affects 1% to 2% of pregnant women and is a leading cause of
maternal and perinatal morbidity and mortality worldwide. The clinical syndrome of PE …

OBJECTIVE: To test the hypothesis that a combination of PP13, PAPP-A and first-trimester
uterine artery Doppler would improve the prediction of pre-eclampsia. METHODS: This is a …

An antiangiogenic state might constitute a terminal pathway for the multiple aetiologies of
pre-eclampsia, especially those resulting from placental abnormalities. The levels of …

In the field of preeclampsia, enormous efforts are ongoing to identify biomarkers predicting
the syndrome already in the first trimester of pregnancy. At the same time, there is the need …

Objective: An imbalance between maternal angiogenic/anti-angiogenic factors
concentrations has been observed in preeclampsia (PE) and other obstetrical syndromes …